# AndroMETa-CRC (NCT07525206)

> A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07525206
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AbbVie
- Conditions: Colorectal Cancer
- Interventions: Telisotuzumab adizutecan; Bevacizumab; Trifluridine/Tipiracil
- Enrollment: 990
- Primary outcome: Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Phase 3: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=andrometa-crc-nct07525206